The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4602 as montherapy or in combination with other anti-tumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-4602 for advanced solid tumors.
18-80 years old;
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Stage I: subjects with pathologically confirmed locally advanced unresectable or metastatic solid tumors, who have failed at least 1 line of standard treatment;
Provide archived or fresh tumor tissue；HER2 expression is required for subjects in Stage I;
Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases；
Subjects with peripheral neuropathy；
Have received anti-cancer treatment within 4 weeks prior the first dose of study treatment;
Are participating in another clinical study or have received the last dose in a clinical study less than 4 weeks from the first dose;